ArticleClinical and experimental pediatrics2026
Intramuscular and subcutaneous gonadotropin-releasing hormone agonist tests for central precocious puberty in girls: a randomized controlled trial.
Article in Clinical and experimental pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Background: Central precocious puberty (CPP) results from premature activation of the hypothalamic-pituitary-gonadal axis. Although the standard intravenous gonadotropin-releasing hormone (GnRH) stimulation test is often inaccessible, a subcutaneous (SC) GnRH analogue (GnRHa) test is used. However, the conventional SC route presents logistical challenges including prolonged observation times and the need for multiple blood draws. Thus, identifying a more efficient administration route could optimize clinical workflows and enhance patient comfort. This study aimed to determine whether intramuscular (IM) administration is comparable to SC administration by analyzing the time to peak luteinizing hormone (LH) levels. Purpose: To evaluate and compare the time to peak LH levels and diagnostic timing of IM versus SC GnRH stimulation tests in girls with CPP. Methods: This randomized controlled trial enrolled 92 girls with suspected CPP. Participants were assigned via 2:1 block randomization to receive 100 mcg triptorelin acetate via SC (n=62) or IM (n=30) injection. Serial blood samples for LH and follicle-stimulating hormone were collected at 0, 30, 60, 90, and 120 minutes. Results: There were no significant differences between the 2 groups in demographic characteristics. Peak LH responses were most frequent at 30 minutes in both groups (IM, 33.3%; SC, 35.5%; P=0.88). The mean LH levels at 30, 60, 90, and 120 minutes did not differ significantly between groups. Diagnostic confirmation of CPP occurred within 30 minutes in 96.7% and 96.8% of patients in the IM and SC groups, respectively. Conclusion: The IM GnRH stimulation test was comparable to the standard SC test in terms of LH response magnitude and timing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.